TAVR technology is designed to allow some patients, who may not be candidates for conventional open-heart valve replacement surgery due to excessive risk, to obtain a life-saving valve. Treatment of aortic valve disease remains a significant and growing unmet clinical need. TAVR devices may be implanted via multiple vascular routes (via the femoral artery – “transfemoral”, via the subclavian artery, or between the ribs via the apex of the heart – “transapical”) and is considered to be a minimally invasive procedure versus conventional open-heart valve surgery.
TVI seeks to help improve patient care and make minimally invasive valve replacement feasible for a broader range of patients. TVI designs and develops “next generation” transcatheter valves and adjuvant technology to treat both native and bioprosthetic valve dysfunction.
TVI was founded in 2009 by Dr. John Webb and Dr. David Wood. The company is located in Vancouver, British Columbia, Canada. Dr. Webb is currently the McLeod Professor of Heart Valve Interventions at the University of British Columbia and has over 200 publications in peer reviewed journals, including Circulation and the Journal of the American College of Cardiology. As leader of the first group to develop transarterial and transapical aortic valve implantation, as currently executed, Dr. Webb has performed or supervised over 800 procedures in Vancouver and approximately 50 centers throughout North America, Europe, and Australasia. Dr. Wood obtained subspecialty training in structural and interventional cardiology as well as advanced cardiac imaging in both Vancouver and New York City. He has over 40 publications in peer reviewed journals and collaborates daily with Dr. Webb in Vancouver to help refine and improve transcatheter valve therapies.